Home / Market News / $MYGN
benzinga Corporate Catalyst Impact 90/100 ● positive

Myriad Genetics To Sell Its Prenatal Health Testing Business, Including Prequel, Foresight, SneakPeek And FirstGene Tests, To Labcorp For $210M In Cash Plus Inventory Value

Oct 20, 2026, 12:35 PM UTC · Primary ticker $MYGN

Myriad Genetics is selling its entire Prenatal Health testing business, including key brands, to Labcorp for $210 million in cash plus inventory. This divestiture represents a significant strategic shift for Myriad and a notable expansion for Labcorp in the prenatal testing market.

Myriad Genetics is selling its Prenatal Health testing business, which includes Prequel, Foresight, SneakPeek, and FirstGene tests, to Labcorp for $210 million in cash plus inventory value. This is a significant strategic move for Myriad, as it divests a business that generated substantial revenue (over 600,000 patients served in the last 12 months) and provides a cash infusion. For Labcorp, the acquisition is expected to add approximately $160 million in revenue in the first year and be slightly accretive to adjusted earnings, reaching average diagnostics segment margins by year two. This deal allows Labcorp to expand its comprehensive laboratory services and patient network, while Myriad can focus on its core areas. Short-term, MYGN may see a positive reaction due to the cash injection and strategic focus, while LH benefits from immediate revenue growth and market share expansion. The key opportunity for traders is to assess the long-term strategic implications for both companies and how this divestiture impacts Myriad's future growth trajectory and Labcorp's integration capabilities.

$MYGN positive Divesting non-core asset, cash infusion
$LH positive Acquiring profitable business, revenue growth
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.